Trial Profile
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Lipid-Altering Efficacy, Safety and Tolerability of MK-0524A in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Niacin/laropiprant (Primary) ; Niacin
- Indications Hypercholesterolaemia; Hyperlipoproteinaemia type V
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 13 Jun 2019 Trial has been completed in Spain and Denmark.
- 05 May 2009 Actual end date (Dec 2006) added as reported by ClinicalTrials.gov.
- 01 Dec 2008 Results published in the International Journal of Clinical Practice.